Solara Active Pharma Sciences Limited has informed the Exchange regarding a press release dated May 10, 2025, titled "Completion of USFDA inspection in Ambernath facility".
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Solara Active Pharma Sciences announced that the US FDA inspected its Ambernath (Maharashtra) multi-product API manufacturing facility from May 5 to May 9, 2025, and concluded the inspection with Zero Form 483 inspectional observations, placing the site in an 'Acceptable State of Compliance.' This marks the third consecutive successful inspection with Zero 483s across Solara's manufacturing network. The Ambernath facility, established in 2004, is one of six manufacturing sites and is also approved by regulators including EDQM, WHO, PMDA, and KFDA. The company described the outcome as evidence of its commitment to world-class quality and compliance, which is a key pillar of its growth strategy.
Positive for shareholders — a clean USFDA inspection (Zero 483s) means the Ambernath facility faces no regulatory roadblocks and can continue supplying APIs to the US market, supporting revenue continuity and reinforcing the company's compliance track record. This typically boosts investor confidence in the stock.